
[Federal Register Volume 80, Number 13 (Wednesday, January 21, 2015)]
[Notices]
[Pages 2991-2995]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-00839]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-74055; File No. SR-CME-2015-001]


Self-Regulatory Organizations; Chicago Mercantile Exchange Inc.; 
Notice of Filing and Immediate Effectiveness of Proposed Rule Change 
Related to Clearing of Certain iTraxx Europe Index Untranched CDS 
Contracts on Indices Administered by Markit

January 14, 2015.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 
(``Act'' or ``Exchange Act''),\1\ and Rule 19b-4 thereunder,\2\ notice 
is hereby given that on January 5, 2015, Chicago Mercantile Exchange 
Inc. (``CME'') filed with the Securities and Exchange Commission 
(``Commission'') the proposed rule change as described in Items I, II 
and III below, which Items have been prepared primarily by CME. CME 
filed the proposal pursuant to Section 19(b)(3)(A) of the Act,\3\ and 
Rule 19b-4(f)(4)(ii) \4\ thereunder, so that the proposal was effective 
upon filing with the Commission. The Commission is publishing this 
notice to solicit comments on the proposed rule change from interested 
persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A).
    \4\ 17 CFR 240.19b-4(f)(4)(ii).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance 
of the Proposed Rule Change

    The purpose of the proposed changes to CME's clearing rules (the 
``CDS Product Rules'') is to enable CME to offer clearing of certain 
iTraxx Europe index untranched CDS contracts on indices administered by 
Markit (``iTraxx Contracts''). All capitalized terms not defined herein 
shall have the meaning given to them in the CDS Product Rules.
    CME is submitting the proposed amendments to the iTraxx Chapters 
(as defined in Item II.A. below) to become effective immediately, 
subject to receiving all regulatory approvals.

II. Self-Regulatory Organization's Statement of the Purpose of, and 
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, CME included statements 
concerning the purpose and basis for the proposed rule change and 
discussed any comments it received on the proposed rule change. The 
text of these statements may be examined at the places specified

[[Page 2992]]

in Item IV below. CME has prepared summaries, set forth in sections A, 
B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and 
Statutory Basis for, the Proposed Rule Change

1. Purpose
    CME is registered as a Derivatives Clearing Organization (``DCO'') 
with the Commodity Futures Trading Commission (``CFTC'') and offers 
clearing services for many different futures and swaps products, 
including certain CDS index products. Currently, CME offers clearing of 
(i) the Markit CDX North American Investment Grade Index Series 8 and 
forward and (ii) the Markit CDX North American High Yield Index Series 
13 and forward ((i) and (ii) collectively, the ``CDX Contracts'').
    The primary purpose and effect of the proposed changes to the CDS 
Product Rules that are described in this filing is to enable CME to 
offer clearing of iTraxx Contracts under CME's authority to act as a 
DCO. iTraxx Contracts have similar terms to CDX Contracts currently 
cleared by CME. Accordingly, the proposed rules largely mirror the CME 
rules for CDX Contracts, with certain modifications that reflect the 
differing underlying reference entities, different standard currencies 
and other logistical differences in how the markets and documentation 
for iTraxx Contracts operate. The iTraxx Contracts reference the iTraxx 
Europe index, the current series of which consists of 125 European 
corporate reference entities. The credit protection offered by iTraxx 
Contracts and any Restructuring European Single Name CDS Contract 
consistent with market convention and widely used standard terms 
documentation, can be triggered by credit events including failure to 
pay, bankruptcy, restructuring and, in respect of transactions that 
will reference the 2014 ISDA Definitions (such transactions, ``2014 
Definitions Transactions'') governmental intervention. iTraxx Contracts 
will be denominated in Euro.
    CME notes that, upon the occurrence of a restructuring credit event 
with respect to a reference entity that is a component of an iTraxx 
Contract, such reference entity will be ``spun out'' and maintained as 
a separate single-name CDS contract (a ``Restructuring European Single 
Name CDS Contract'') until settlement. If neither of the counterparties 
elects to trigger settlement, the positions in the Restructuring 
European Single Name CDS Contract will be maintained at CME until 
maturity of the index or the occurrence of a subsequent credit event 
for the same reference entity. However, CME will not permit market 
participants to increase, close out or otherwise affect the size of a 
position in a Restructuring European Single Name CDS Contract (other 
than due to the occurrence of a credit event, default management 
process, close out of a defaulting customer's positions, or withdrawal 
from clearing membership in accordance with CME rules) \5\ and CME has 
included language in its proposed rule change to this effect. CME notes 
that it may impose an increase or decrease in the position of a 
Restructuring European Single Name CDS Contract through its default 
management process under applicable CME rules.\6\
---------------------------------------------------------------------------

    \5\ Currently, those rules are CME Rules 230, 8H10, 8H14, 8H26, 
8H27, 8H802, 8H913, and 8H975.
    \6\ Currently, those rules are CME Rules 230, 8H10, 8H14, 8H26, 
8H27, 8H802, and 8H975.
---------------------------------------------------------------------------

    To the extent that a Restructuring European Single Name CDS 
Contract is created, CME will either (i) obtain any relief needed to 
permit a clearing member to maintain customer money, securities, and 
property received by the clearing member to margin, guarantee, or 
secure customer positions in cleared CDS Contracts, which include both 
swaps and security-based swaps, in a segregated account established and 
maintained in accordance with Section 4d(f) of the Commodity Exchange 
Act (``CEA'') and the rules thereunder for the purpose of clearing such 
positions under a programme to comingle and portfolio margin CDS, or 
(ii) will hold customer positions in Restructuring European Single Name 
CDS Contracts and any margin in connection with such Restructuring 
European Single Name CDS Contracts in segregated accounts or take any 
other action required in order to comply with the provisions of the 
Exchange Act or any order or relief thereunder.
(i) Description of Proposed CME Rule Changes
    CME is proposing to amend its CDS Product Rules by amending Chapter 
801 and adding new Chapters 800: Part B, 804: Part B, 805: Part C, 806: 
Part B and Appendix 805: Part B (collectively, the ``iTraxx 
Chapters''). CME is also proposing to add new Chapters 805: Part B, 
806: Part A and Appendix 805: Part A (together, the ``2014 iTraxx 
Chapters'').
    CME also proposes to make corresponding changes to its CDS Manual 
of Operations to provide for the clearance of iTraxx Contracts. 
Specifically, amendments have been made where CDX Contracts are 
described as the only CDS Contracts which CME clears and a deletion has 
been made to reflect that Restructuring will be a credit event for 
iTraxx Contracts. Also, a reference which relates to outdated aspects 
of the CDS risk model is proposed to be deleted.
    CME will update its list of products eligible for clearing, which 
is available on its Web site at http://www.cmegroup.com/trading/cds/cleared-cds-product-specs.xls, to incorporate the additional cleared 
products. Upon Commission approval, CME intends to provide for the 
clearance of the following European Indices: Markit iTraxx Europe Main 
3Y: Series 17 and all subsequent Series, up to and including the 
current on-the-run Series, Markit iTraxx Europe Main 5Y: Series 17 and 
all subsequent Series, up to and including the current on-the-run 
Series, Markit iTraxx Europe Main 7Y: Series 17 and all subsequent 
Series, up to and including the current on-the-run Series, Markit 
iTraxx Europe Main 10Y: Series 17 and all subsequent Series, up to and 
including the current on-the-run Series, and Markit iTraxx Europe 
Crossover 5Y: Series 17 and all subsequent Series, up to and including 
the current on-the-run Series.
    Certain iTraxx Contracts which CME proposes to clear will, 
following the implementation date of the 2014 ISDA Definitions, be 
bifurcated such that certain component transactions will continue to 
reference the 2003 Credit Derivatives Definitions published by ISDA, as 
supplemented in 2009 (the ``2003 ISDA Definitions'') (such 
transactions, ``2003 Definitions Transactions''), and certain other 
component transactions will be 2014 Definitions Transactions. 
Consistent with CME's treatment of CDS products with different product 
terms, CME will position iTraxx Component Transactions that do not 
incorporate the same set of credit derivatives definitions as separate 
cleared CDS Contracts upon the occurrence of a restructuring credit 
event in respect of such iTraxx Component Transactions. As a result of 
the above mentioned bifurcation, CME proposes to split Chapters 800, 
804 and 805 of its current rules into separate sub-parts and to 
introduce a new Chapter 806 and a new Appendix to Chapter 805 (each of 
which will also be split into sub-parts) to allow for the separate 
treatment of iTraxx Component Transactions depending on whether such 
transactions are 2014 Definitions Transactions or 2003 Definitions 
Transactions.

[[Page 2993]]

    The computation of the spread risk, interest rate risk, and 
liquidity and concentration risk components in CME's risk model 
framework is described in CME's proposed rule change to revise its risk 
model for CDS (the ``CDS Risk Model'') \7\ and will be agnostic to 
whether the 2003 ISDA Definitions or the 2014 ISDA Definitions are 
applicable, therefore allowing risk offsets across iTraxx Component 
Transactions that refer to the same reference entity but that do not 
incorporate the same set of credit derivatives definitions. No risk 
offsets will be provided for computation of idiosyncratic risk 
requirements for iTraxx Component Transactions which refer to the same 
reference entity but that do not incorporate the same set of credit 
derivatives definitions. The applicability of the post credit event 
risk requirement will be based on whether a credit event occurs by 
reference to the relevant credit derivatives definitions (2003 ISDA 
Definitions or the 2014 ISDA Definitions) and the relevant transaction 
type that is applicable to an iTraxx Component Transaction. The post 
credit event risk requirement will be computed on a net notional basis 
for a particular reference entity within an iTraxx index where a Credit 
Event has been determined under the relevant credit derivatives 
definitions.
---------------------------------------------------------------------------

    \7\ See Securities Exchange Act Release No. 34-73849 (Dec. 16, 
2014), 79 FR 76428 (Dec. 22, 2014) (SR-CME-2014-51).
---------------------------------------------------------------------------

(a) Chapter 800 (Credit Default Swaps: Part B)
    CME proposes to add a sub-part to Chapter 800 entitled ``Credit 
Default Swaps: Part B.'' Chapter 800: Part B provides the meanings of 
capitalized terms that are used but not defined within the proposed 
rules and the location of the meanings of any terms used in the 
proposed rules but not defined within Chapter 800: Part B. In addition, 
CME has included CME Rule 80002.B (Interpretation), which provides for 
the interpretation of certain contractual terms used within the 
proposed rules, and CME Rule 80003.B (Notices and Clearing House System 
Failures), which provides for how notices are to be provided by, or to, 
CME and also for the extension of applicable deadlines for the delivery 
of notices if CME, or any of its clearing members, is unable to deliver 
or receive notices due to a failure of the relevant CME internal 
system. CME notes that CME Rule 80002.B and CME Rule 80003.B (each as 
described in the aforementioned sentence) are substantially similar to 
CME Rule 80002 and CME Rule 80003, respectively, that are provided in 
the currently published Chapter 800.
(b) Chapter 801 (CDS Contracts)
    CME proposes to amend Chapter 801 (CDS Contracts) to include in CME 
Rule 80103.C (Eligible CDS) an additional provision which describes 
when an iTraxx Contract will be eligible for clearing and other 
conforming, clarification changes and drafting improvements.
(c) Chapter 804 (CME CDS Risk Committee: Part B)
    CME proposes to add a sub-part to Chapter 804 entitled ``CME CDS 
Risk Committee: Part B'' to apply only in connection with 2003 
Definitions Transactions. Chapter 804: Part B will not contain any 
iTraxx specific provisions, but will be created in anticipation of the 
currently published Chapter 804 being updated to operate in conjunction 
with the 2014 ISDA Definitions. Chapter 804: Part B is substantially 
similar to the currently published Chapter 804 with the exception that 
Chapter 804: Part B grants an additional authority to the CDS RC to 
determine matters of contractual interpretation relevant to market 
standard documentation incorporated into the terms of a CDS Contract. 
In addition, modifications have been made in order to ensure alignment 
of the CDS Product Rules with the current market practices (as proposed 
by ISDA) to clarify the circumstances under which the CDS RC may make 
such determinations to avoid determinations that are inconsistent with 
DC determinations, and other conforming, clarification changes and 
drafting improvements.
(d) Chapter 805 (CME CDS Physical Settlement: Part B), Chapter 805 (CME 
CDS Physical Settlement: Part C) and CDS Participant Provisions 
Appendix
    CME proposes to add two sub-parts to Chapter 805 entitled ``CME CDS 
Physical Settlement: Part B'' and ``CME CDS Physical Settlement: Part 
C.'' CME notes that it is anticipated that the currently published 
Chapter 805 will be amended and referred to as ``Part A'' as part of 
CME's amendments to its CDS Product Rules to incorporate the 2014 ISDA 
Definitions, but that such amendments will not take into account the 
required iTraxx specific changes that would need to be made to Chapter 
805 in order for CME to clear iTraxx Contracts. Chapter 805: Part B 
will apply only in connection with 2014 Definitions Transactions and 
Chapter 805: Part C will apply only in connection with 2003 Definitions 
Transactions. In general, both Chapter 805: Part B and Chapter 805: 
Part C provide for the physical settlement process that will apply as 
the fallback settlement method with respect to iTraxx Contracts and 
Restructuring European Single Name CDS Contracts in circumstances where 
auction settlement does not apply. The substance of the new provisions 
is based on the fallback physical settlement provisions that apply for 
CDX Contracts, with some additional features addressing the product 
terms particular to iTraxx Contracts and some further clarification and 
detail in light of the increased likelihood of physical settlement 
being applicable to iTraxx Contracts and Restructuring European Single 
Name CDS Contracts. These additional features are described in further 
detail below.
    CME Rules 80502.B.A and 80502.C.A (Matched Pair Notice) provide 
additional detail in relation to the matching process. The additions do 
not substantively alter the CDS Product Rules but rather, seek to 
provide greater clarity with respect to the current matching process 
and how such process will work in respect of iTraxx Contracts.
    CME Rules 80502.B.C and 80502.C.D (Notices) have been updated to 
provide additional detail around the notice procedures in light of the 
more complex notice requirements following a restructuring credit event 
with respect to an iTraxx Component Transaction or a Restructuring 
European Single Name CDS Contract. As a result of the more complex 
notice requirements, CME proposes to insert in CME Rule 80502.B.D and 
80502.C.E (Disputes as to Notices) a more comprehensive dispute process 
in relation to the effective delivery of notices to preserve more 
accurately the economic effect of the delivery of certain notices.
    CME Rule 80503.B and 80503.C (Physical Settlement of Non DVP 
Obligations) provide greater clarity with respect to the timing of the 
delivery of Non DVP Obligations and payment of the related portion of 
the Physical Settlement Amount. In addition, the allocation of any 
expenses incurred in connection with physical settlement is now 
expressly contemplated.
    CME Rule 80507.B and 80507.C (Clearing House Guarantee of Matched 
Pair CDS Contracts) and CME Rule 80508.B and 80508.C (Failure to 
Perform Under Matched Pair CDS Contracts) have been updated to align 
the matching process with the general physical settlement provisions of 
CME as set out in Chapter 7 (Delivery Facilities and Procedures).

[[Page 2994]]

    CME also proposes to add an Appendix to Chapter 805 which will be 
split into two sub-parts. Appendix: Part A will apply only in 
connection with 2014 Definitions Transactions and Appendix: Part B will 
apply only in connection with 2003 Definitions Transactions. The 
Appendix primarily sets out provisions dealing with physical settlement 
and the delivery of notices between clearing members and their 
customers. The provisions are intended to facilitate the delivery of 
notices and physical settlement. The Appendix is intended to apply to 
all CDS contracts; however, the provisions are for the convenience of 
the clearing members and their customers and will not bind CME. The 
Appendix includes provisions addressing (i) the timing of the delivery 
of physical notices in a chain of transactions between the clearing 
house, the clearing members and their customers, (ii) when notices, 
requests or instructions between a clearing member and its customer are 
effective, (iii) the delivery of deliverable obligations between a 
clearing member and its customer, (iv) circumstances where a fallback 
to cash settlement will be deemed to apply, (v) buy-in of bonds not 
delivered and the circumstances around the effective delivery of a buy-
in notice, and (vi) alternative procedures relating to loans not 
delivered and the circumstances around the effective delivery of an 
alternative loan buyer notice. The Appendix will only be relevant to 
CME CDS Physical Settlement, and not when auction settlement applies 
and is therefore unlikely to be applicable to settlement in most cases.
(e) Chapter 806 (iTraxx Europe Index Untranched CDS Contracts: Part A) 
and Chapter 806 (iTraxx Europe Index Untranched CDS Contracts: Part B)
    CME proposes to add Chapter 806 which will be split into two sub-
parts entitled ``iTraxx Europe Index Untranched CDS Contracts: Part A'' 
and Chapter 806 ``iTraxx Europe Index Untranched CDS Contracts: Part 
B.'' Chapter 806: Part A will apply only in connection with 2014 
Definitions Transactions and Chapter 806: Part B will apply only in 
connection with 2003 Definitions Transactions.
    CME Rules 80601.A and 80601.B (Scope of Chapter) set forth the 
applicable standard terms relevant for iTraxx Component Transactions 
and where the terms and conditions for Restructuring European Single 
Name CDS Contracts are set out. Further, it is clarified that unless a 
restructuring credit event occurs, no iTraxx Component Transaction will 
be fungible with a European single name CDS contract.
    CME Rules 80602.A and 80602.B (Contract Terms) reflect or 
incorporate the basic contract specifications for iTraxx Contracts and 
Restructuring European Single Name CDS Contracts and are substantially 
similar to CME Rule 80202 (Contract Terms) for CDX Contracts. Similarly 
CME Rules 80603.A and 80603.B (Contract Modifications) are 
substantially similar to CME Rule 80203 (Contract Modifications) for 
CDX Contracts, except for conforming changes.
    In addition, CME Rule 80604.A and 80604.B (Restructuring) have been 
added to reflect the fact that restructuring is a credit event for 
iTraxx Contracts and Restructuring European Single Name CDS Contracts, 
that governmental intervention is a credit event for certain 2014 
Definitions Transactions, and that Restructuring European Single Name 
CDS Contracts may be created. In addition, CME has inserted (i) a 
notice delivery procedure to address the delivery of restructuring 
credit event notices and notices to exercise movement options, (ii) a 
process to separate any matched restructuring pairs following an 
announcement that a restructuring credit event did not in fact occur, 
(iii) provisions relating to the identification of the reference 
obligation for a Restructuring European Single Name CDS Contract, (iv) 
a comprehensive dispute process in relation to the effective delivery 
of restructuring credit event notices and notices to exercise movement 
options that are delivered directly (not via DTCC), and (v) a procedure 
for CME to communicate certain information received from DTCC, or from 
its clearing members, as applicable, to the relevant clearing members 
via reports.
(ii) CDS Risk Model
    CME has submitted to the Commission, pursuant to Section 
19(b)(3)(A) of the Exchange Act\8\ and Rule 19b-4(f)(4)(ii)\9\ 
thereunder, the proposed CDS Risk Model, for the purposes of enabling 
CME to offer clearing of additional CDS instruments, including iTraxx 
Contracts, within the CDS Risk Model.\10\
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 78s(b)(3)(A).
    \9\ 17 CFR 240.19b-4(f)(4)(ii).
    \10\ See supra note 7.
---------------------------------------------------------------------------

2. Statutory Basis
    CME has identified iTraxx Contracts as products that have become 
increasingly important for market participants to manage risk with 
respect to European corporate and financial entities' credit risk. CME 
believes the proposed changes to its CDS Product Rules are consistent 
with the requirements of the Exchange Act including Section 17A of the 
Exchange Act.\11\ The proposed changes which will facilitate CME's 
clearance of iTraxx Contracts would expand CME's CDS index product 
offering and would therefore provide investors with an expanded range 
of derivatives products for clearing. CME notes that the facilitation 
of clearance of iTraxx Contracts is of particular importance as the 
CFTC has determined that iTraxx Contracts that are subject to a 5Y or 
10Y tenor are subject to mandatory clearing under Section 2(h) of the 
CEA.\12\ As such, the proposed changes are designed to promote the 
prompt and accurate clearance and settlement of securities transactions 
and, to the extent applicable, derivatives agreements, contracts, and 
transactions, to assure the safeguarding of securities and funds which 
are in the custody or control of the clearing agency or for which it is 
responsible, and, in general, to protect investors and the public 
interest consistent with Section 17A(b)(3)(F) of the Exchange Act.\13\
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78q-1.
    \12\ 7 U.S.C. 2(h).
    \13\ 15 U.S.C. 78q-1(b)(3)(F).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    CME does not believe that the proposed rule change would have any 
impact, or impose any burden, on competition. On the contrary, the 
clearance of iTraxx Contracts will promote competition since some of 
CME's competitors, including ICE Clear Credit LLC, ICE Clear Europe 
Limited and LCH.Clearnet S.A., already offer clearing of iTraxx 
Contracts. CME will therefore be able to provide market participants 
with an expanded choice for clearing iTraxx Contracts.

C. Self-Regulatory Organization's Statement on Comments on the Proposed 
Rule Change Received From Members, Participants, or Others

    CME has not solicited, and does not intend to solicit, comments 
regarding this proposed rule change. CME has not received any 
unsolicited written comments from interested parties.

III. Date of Effectiveness of the Proposed Rule Change and Timing for 
Commission Action

    The foregoing rule change has become effective upon filing pursuant 
to Section

[[Page 2995]]

19(b)(3)(A)\14\ of the Act and Rule 19b-4(f)(4)(ii)\15\ thereunder.
---------------------------------------------------------------------------

    \14\ 15 U.S.C. 78s(b)(3)(A).
    \15\ 17 CFR 240.19b-4(f)(4)(ii).
---------------------------------------------------------------------------

    CME asserts that this proposal constitutes a change in an existing 
service of CME that (a) primarily affects the clearing operations of 
CME with respect to products that are not securities, including futures 
that are not security futures, and swaps that are not security-based 
swaps or mixed swaps, and forwards that are not security forwards; and 
(b) does not significantly affect any securities clearing operations of 
CME or any rights or obligations of CME with respect to securities 
clearing or persons using such securities-clearing service, which 
renders the proposed change effective upon filing. CME believes that 
the proposal does not significantly affect any securities clearing 
operations of CME because CME recently filed a proposed rule change 
that clarified that CME has decided not to clear security-based swaps, 
except in a very limited set of circumstances.\16\ The rule filing 
reflecting CME's decision not to clear security-based swaps removed any 
ambiguity concerning CME's ability or intent to perform the functions 
of a clearing agency with respect to security-based swaps. Therefore, 
this proposal will not have an effect on any securities clearing 
operations of CME.
---------------------------------------------------------------------------

    \16\ See Securities Exchange Act Release No. 34-73615 (Nov. 17, 
2014), 79 FR 69545 (Nov. 21, 2014) (SR-CME-2014-49). The only 
exception is with regards to Restructuring European Single Name CDS 
Contracts created following the occurrence of a Restructuring Credit 
Event in respect of an iTraxx Component Transaction. The clearing of 
Restructuring European Single Name CDS Contracts will be a necessary 
byproduct after such time that CME begins clearing iTraxx Contracts.
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed change, 
the Commission summarily may temporarily suspend such rule change if it 
appears to the Commission that such action is necessary or appropriate 
in the public interest, for the protection of investors, or otherwise 
in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views and 
arguments concerning the foregoing, including whether the proposed rule 
change is consistent with the Act. Comments may be submitted by any of 
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml), or
     Send an email to rule-comments@sec.gov. Please include 
File No. SR-CME-2015-001 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities 
and Exchange Commission, 100 F Street NE., Washington, DC, 20549-1090.

All submissions should refer to File Number SR-CME-2015-001. This file 
number should be included on the subject line if email is used. To help 
the Commission process and review your comments more efficiently, 
please use only one method. The Commission will post all comments on 
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all 
written statements with respect to the proposed rule change that are 
filed with the Commission, and all written communications relating to 
the proposed rule change between the Commission and any person, other 
than those that may be withheld from the public in accordance with the 
provisions of 5 U.S.C. 552, will be available for Web site viewing and 
printing in the Commission's Public Reference Room, 100 F Street NE., 
Washington, DC 20549, on official business days between the hours of 
10:00 a.m. and 3:00 p.m. Copies of such filing also will be available 
for inspection and copying at the principal office of CME and on CME's 
Web site at http://www.cmegroup.com/market-regulation/rule-filings.html.
    All comments received will be posted without change; the Commission 
does not edit personal identifying information from submissions. You 
should submit only information that you wish to make available 
publicly.
    All submissions should refer to File Number SR-CME-2015-001 and 
should be submitted on or before February 11, 2015.

    For the Commission, by the Division of Trading and Markets, 
pursuant to delegated authority.\17\
Brent J. Fields,
Secretary.
---------------------------------------------------------------------------

    \17\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

[FR Doc. 2015-00839 Filed 1-20-15; 8:45 am]
BILLING CODE 8011-01-P


